ALS-8112

Cat. No.:	HY-12983		
CAS No.:	1445379-92	2-9	
Molecular Formula:	C ₁₀ H ₁₃ ClFN ₃	04	
Molecular Weight:	293.68		
Target:	RSV		
Pathway:	Anti-infecti	on	
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 47 mg/mL (160.04 mM) * "≥" means soluble, but saturation unknown.				
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	3.4051 mL	17.0253 mL	34.0507 mL
		5 mM	0.6810 mL	3.4051 mL	6.8101 mL
		10 mM	0.3405 mL	1.7025 mL	3.4051 mL
	Please refer to the solubility information to select the appropriate solvent.				
In Vivo	 Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline Solubility: ≥ 2.5 mg/mL (8.51 mM); Clear solution Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.51 mM); Clear solution 				

Description	ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS- 8112 inhibits RSV polymerase with an IC ₅₀ of 0.02 μM.			
IC ₅₀ & Target	IC50: 0.02 μM (RSV) ^[1]			
In Vitro	The 5'-triphosphate form of ALS-8112 (ALS-8112-TP) is the active form of the drug and selectively inhibits RSV polymerase through chain termination of RNA synthesis ^[2] . ALS-008112 enters various types of epithelial cells in the respiratory tract and is subsequently phosphorylated to form an intracellular nucleoside triphosphate with a half-life of approximately 29 hours. The nucleoside triphosphate analogue inhibits RSV replication by means of chain termination ^[3] . ALS-8112 is a pan-strain			

Product Data Sheet

HO

 $\rm NH_2$

N

Ó

'''F

اً OH

CI

inhibitor of RSV replication in vitro. The RNA transcription activity of the RSV–RNP complex is dose-proportionally inhibited by ALS-8112-TP with an IC_{50} of 0.020 ± 0.008 μ M^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ΟΤΟϹΟΙ	
Cell Assay ^[4]	ALS-8112 and its prodrug ALS-8176 are stored at 4°C in dimethyl sulfoxide (DMSO), and diluted in water. HEp-2 cells per v are plated in a 96-well plate. Each compound is serially diluted (1:3) up to 9 distinct concentrations. Cells are pre-incuba with compounds for 24 hours at 37°C in a 5% CO ₂ atmosphere. After 24 hours of pre-incubation with compounds, RSV A2 Long, or B1 at a multiplicity of infection (MOI) of 0.5 is added to the cells, except for the background controls. The plate is then incubated for additional 4 days in the same conditions and at the end of the incubation 50 μL the supernatant from
	each well of the plate is collected ^[4] .
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Antiviral Res. 2018 Feb;150:79-92.
- Microorganisms. 2023 Jun 18, 11(6), 1608.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wang G, et al. Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem. 2015 Feb 26;58(4):1862-78.

[2]. Jordan PC, et al. Activation Pathway of a Nucleoside Analog Inhibiting Respiratory Syncytial Virus Polymerase. ACS Chem Biol. 2017 Jan 20;12(1):83-91.

[3]. DeVincenzo JP, et al. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med. 2015 Nov 19;373(21):2048-58.

[4]. Deval J, et al. Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate. PLoS Pathog. 2015 Jun 22;11(6):e1004995.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA